3
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T23589 |
9-Isopropylolomoucine
9 Isopropylolomoucine,N9 Isopropylolomoucine,N9Isopropylolomoucine,N9-Isopropylolomoucine |
CDK | Cell Cycle/Checkpoint |
9-Isopropylolomoucine (N9-Isopropylolomoucine) 是一种细胞周期蛋白依赖性激酶抑制剂,是一种硫嘌呤。 | |||
T21588 |
Olomoucine
|
ERK; CDK | Cell Cycle/Checkpoint; MAPK |
Olomoucine 是 Cdk2/cyclin A、Cdc2/CyclinB、CDK2/CyclinE、CDK5/p35 和 ERK1/p44 MAP 激酶的 ATP 竞争性抑制剂,IC50 分别为 7、7、7、3 和 25 µM。 Olomoucine 调节细胞周期并表现出抗黑色素肿瘤活性。 | |||
T35696 |
Olomoucine II
|
||
Olomoucine II is an inhibitor of cyclin-dependent kinases (CDKs; IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 μM for Cdk1, -2, -4, -7, and -9, respectively).1It is selective for CDKs over 10 additional kinases (IC50s = >100 μM for all) but does inhibit ERK2 (IC50= 32 μM) and the ATP-binding cassette transporter B1 (ABCB1; IC50= 6.4 μM).1,2Olomoucine II inhibits proliferation of a variety of cancer cells, including those expressing wild-type p53 or mutant p53 (mean IC50s = 7.4 and 10.1 μM, respectively... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T25192 |
Butyrolactone I
Olomoucin,丁酸内酯I |
CDK | Cell Cycle/Checkpoint |
Butyrolactone I (Olomoucin) 是 CDK 和 cdc2 激酶家族的 ATP 竞争性抑制剂。 Butyrolactone I 在非小细胞肺、小细胞肺和前列腺癌细胞系中显示出抗肿瘤作用。 |